ERK and c-Myc signaling in host-derived tumor endothelial cells is essential for solid tumor growth

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Current antitumor microenvironment strategies have limited efficacy due to poor understanding of tumor stromal cell roles.
• Identifying the specific contributions of individual stromal cells is crucial for developing effective cancer therapies.

Purpose of the Study:

• To develop a versatile in vivo system for genetically evaluating individual tumor stromal elements in cancer.
• To define the specific contribution of tumor endothelial cells (ECs) to antitumor activity using a novel anthrax toxin delivery system.

Main Methods:

• Engineered a tumor-selective anthrax toxin that disrupts ERK signaling by targeting the CMG2 receptor.
• Created cell-type-specific CMG2 transgenic mice, specifically expressing CMG2 in tumor ECs.
• Evaluated the toxin's antitumor activity and the role of ERK signaling in tumor ECs.

Main Results:

• Disruption of ERK signaling specifically within tumor ECs was sufficient to halt tumor growth.
• Identified c-Myc as a downstream effector of ERK signaling in tumor ECs.
• Demonstrated the essential role of the MEK-ERK-c-Myc metabolic axis in tumor progression.

Conclusions:

• Targeting the MEK-ERK-c-Myc axis in host-derived tumor ECs with anthrax toxins is a potent strategy for solid tumor therapy.
• This study provides a powerful tool for dissecting the roles of individual stromal cells in cancer development.
• Understanding the specific contributions of tumor ECs to tumor progression opens new avenues for cancer treatment.